IL17A and psoriasis: At present, 11 Food and Drug Administration (FDA)-approved biologic options are available for psoriasis modalities: The TNF-alpha inhibitors adalimumab, infliximab, and certolizumab; the Il-17 inhibitors secukinumab, brodalumab, ixekizumab, and bimekizumab; the Il-23 inhibitors guselkumab, tildrakizumab, and risankizumab; and the Il-12/23 inhibitor ustekinumab [9].